SG153647A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations

Info

Publication number
SG153647A1
SG153647A1 SG200507698-9A SG2005076989A SG153647A1 SG 153647 A1 SG153647 A1 SG 153647A1 SG 2005076989 A SG2005076989 A SG 2005076989A SG 153647 A1 SG153647 A1 SG 153647A1
Authority
SG
Singapore
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
antinoeplastic
neoplasms
Prior art date
Application number
SG200507698-9A
Inventor
Gary Dukart
Joseph Gibbons James Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG153647A1 publication Critical patent/SG153647A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention provides the use of a combination of an mTOR inhibitor and an antinoeplastic alkylating agent in the treatment of neoplasms.
SG200507698-9A 2001-06-01 2002-05-29 Antineoplastic combinations SG153647A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
SG153647A1 true SG153647A1 (en) 2009-07-29

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200507698-9A SG153647A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (en)
JP (1) JP2004532883A (en)
KR (1) KR100875611B1 (en)
CN (1) CN100496485C (en)
AU (2) AU2002259309B2 (en)
BR (1) BR0210101A (en)
CA (1) CA2447732A1 (en)
CO (1) CO5540294A2 (en)
EA (1) EA007530B1 (en)
HU (1) HUP0400006A2 (en)
IL (1) IL158800A0 (en)
MX (1) MXPA03010907A (en)
NO (1) NO20035317L (en)
NZ (1) NZ529877A (en)
PL (1) PL367267A1 (en)
SG (1) SG153647A1 (en)
WO (1) WO2002098416A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2322981C2 (en) 2001-02-19 2008-04-27 Новартис Аг Combination and method for prophylaxis of breast cancer
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
AR046194A1 (en) 2003-11-04 2005-11-30 Mayo Foundation TREATMENT METHOD OF MANTO CELL LYMPHOMA
CN113952338A (en) 2005-02-03 2022-01-21 综合医院公司 Methods of treating gefitinib resistant cancers
CA2626326C (en) * 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2006314444C1 (en) * 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CN101415409B (en) * 2006-04-05 2012-12-05 诺瓦提斯公司 Combinations of therapeutic agents for treating cancer
DK2481409T3 (en) * 2007-03-07 2018-08-06 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2835349T3 (en) 2008-06-17 2021-06-22 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
CN105963313A (en) 2008-08-04 2016-09-28 惠氏有限责任公司 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
CN103721189A (en) * 2013-12-27 2014-04-16 刘玉含 Meningeoma nursing medicine and preparation method thereof
CN105168204A (en) * 2015-09-06 2015-12-23 江志鑫 Pharmaceutical composition containing mitomycin and capable of resisting colon cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
EP0525960B1 (en) * 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
RU2322981C2 (en) * 2001-02-19 2008-04-27 Новартис Аг Combination and method for prophylaxis of breast cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEOERGER B ET AL: "ANTITUMOR ACTIVITY OF THE RAPAMYCIN ANALOG CCI-779 IN HUMAN PRIMITIVE NEUROECTODERMAL TUMOR/MEDULLOBLASTOMA MODELS AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 4, no. 61, 15 February 2001 (2001-02-15), pages 1527-1532 *
SHI Y ET AL: "Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro." CANCER RESEARCH, (1995 MAY 1) 55 (9) 1982-8. , vol. 55, no. 9, - 1995 pages 1982-8 *

Also Published As

Publication number Publication date
MXPA03010907A (en) 2004-02-17
AU2002259309B2 (en) 2008-05-01
HUP0400006A2 (en) 2004-04-28
JP2004532883A (en) 2004-10-28
NO20035317D0 (en) 2003-11-28
CA2447732A1 (en) 2002-12-12
WO2002098416A2 (en) 2002-12-12
EA200301319A1 (en) 2004-04-29
IL158800A0 (en) 2004-05-12
WO2002098416A3 (en) 2003-03-13
KR20040025923A (en) 2004-03-26
BR0210101A (en) 2004-06-08
KR100875611B1 (en) 2008-12-24
PL367267A1 (en) 2005-02-21
EA007530B1 (en) 2006-10-27
NO20035317L (en) 2003-12-22
CN1646120A (en) 2005-07-27
AU2008202690A1 (en) 2008-07-10
CN100496485C (en) 2009-06-10
CO5540294A2 (en) 2005-07-29
EP1392286A2 (en) 2004-03-03
NZ529877A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
SG170612A1 (en) Antineoplastic combinations
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
IL157898A0 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
ECSP056001A (en) ANTINEOPLASTIC COMBINATIONS
SG153647A1 (en) Antineoplastic combinations
TW200503753A (en) Antineoplastic combinations
EG22858A (en) Well treatment fluids comprising chelating agents
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
ECSP034866A (en) ANTINEOPLASTIC COMBINATIONS
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
MXPA03008582A (en) Agents and methods for treatment of cancer.
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002083151A3 (en) Compositions and methods for treating an arthritic condition
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
AP2003002855A0 (en) Inhibitor of monoamine uptake.
IL151871A0 (en) Restenosis treatment
AU2001247560A8 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AU7602100A (en) Method for the identification of agents that inhibit or promote cataracts and uses thereof
GB0012250D0 (en) The treatment of intimal hyperplasia, and materials for use therein
AU2002364385A8 (en) Implantable device and the use thereof
MXPA05003282A (en) Immediate release dosage form comprising shell having openings therein.
GB0112689D0 (en) Dispenser and treatment means
AU2002324395A1 (en) Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents